Abstract:Aberrant DNA methylation plays a critical role in the development and progression of cancer. Failure to demethylate and to consequently reactivate methylation-silenced genes in cancer contributes to chemotherapeutic resistance, yet the regulatory mechanisms of DNA demethylation in response to chemotherapeutic agents remain unclear. Here, we show that promyelocytic leukemia (PML) recruits ten-eleven translocation dioxygenase 2 (TET2) to regulate DNA modification and cell proliferation in response to chemotherapeutic agents. TET2 was required by multiple chemotherapeutic agents (such as doxorubicin) to promote 5-hydroxymethylcytosine (5hmC) formation. Stable isotope labeling with amino acids in cell culture, followed by immunoprecipitation-mass spectrometry, identified potential binding partners of TET2, of which PML mostly enhanced 5hmC formation. PML physically bound to TET2 via the PML C-terminal domain and recruited TET2 to PML-positive nuclear bodies. This interaction was disrupted by the PML-RARA t(15;17) mutation, which stems from chromosomal translocation between DNA encoding the C-terminal domain of PML and the retinoic acid receptor alpha (RARA) gene. In response to chemotherapeutic drugs, PML recruited TET2, regulated DNA modification, reactivated methylation-silenced genes, and impaired cell proliferation. Knockout of PML abolished doxorubicin-promoted DNA modification. In addition, PML and TET2 levels positively correlated with improved overall survival in patients with head and neck cancer. These findings shed insight into the regulatory mechanisms of DNA modification in response to chemotherapeutic agents. Significance: Promyeloctic leukemia protein recruits TET2, regulating DNA modification and cell proliferation in response to chemotherapeutic agents. Cancer Res; 78(10); 1-15. ©2018 AACR.

BMK1 is Involved in the Regulation of P53 Through Disrupting the PML–MDM2 Interaction

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth Through Promyelocytic Leukemia Protein.

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth Through Promyelocytic Leukemia Protein

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Targeting RING Domains of Mdm2–MdmX E3 Complex Activates Apoptotic Arm of the P53 Pathway in Leukemia/lymphoma Cells

AXIN is an Essential Co-Activator for the Promyelocytic Leukemia Protein in P53 Activation

BRD4-mediated repression of p53 is a target for combination therapy in AML

PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance Through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type P53 Multidrug-resistant Breast Cancer Cells

FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2

AXL Receptor Signalling Suppresses P53 in Melanoma Through Stabilization of the MDMX–MDM2 Complex

The Phosphatase Mkp1 Is A Transcriptional Target Of P53 Involved In Cell Cycle Regulation

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.

p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP

DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells

The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

Research progress of regulation mechanism of MDMX and CK1αin p53 tumor suppressor protein